LIVE

OCUL

Ocular Therapeutix, Inc.

OCUL

NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B

$9.64

▲ +1.80%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$6.23 - $16.44

P/E

-6.60

Fwd P/E

-6.83

Beta

0.90

Div Yield

0.00%

Avg Vol

3.1M

Shares Out

217.7M

Mkt Cap

$2.1B

Price action

Price chart

Up 0.1% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary bioresorbable hydrogel platform enabling sustained ocular drug delivery
  • FDA-approved commercial products generating revenue and market validation
  • Strategic partnership with Regeneron providing development and commercialization support
  • Differentiated intracameral and intravitreal implant technology with reduced dosing frequency
▼

Bear Case

1 risk

  • Average volatility.

Growth

Moderate growth ahead

DEXTENZA market expansion in post-surgical inflammation and allergic conjunctivitis indications

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+11.5% over 3m

Quality

Excellent

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 4, 2026

“
Q2 26 RECAP

MAY 5, 2026

Reported EPS of -$0.41 vs -$0.32 consensus (-28.1% surprise). Revenue of $10.8M vs $12.7M expected (-15.2%).

EPS miss
Revenue miss

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-28.1%

Next: May 4, 2026

Revenue trend · last 8Q

—

—

+15%

-28%

-18%

-6%

-22%

+1%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$16.4M

$15.4M

$17.1M

$10.7M

$13.5M

$14.5M

$13.3M

$10.8M

Margins · last 8Q

Gross

—

Profit

-821.6%

View full earnings history →

Wall Street consensus

5 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

5

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: HC Wainwright · Jun 18, 2026

View full analyst page →

vs Industry

How OCUL stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.